Biocon’s Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. Key financial metrics, including EPS, are detailed. Crucially, the Board granted in-principle approval to acquire the remaining ~2% equity stake in Biocon Biologics Limited (BBL) from employees and other shareholders. This acquisition, settled via preferential allotment of Biocon shares, will make BBL a wholly-owned subsidiary (WOS).
Outcome of Biocon Board Meeting on February 12, 2026
Biocon Limited announced the key outcomes from its Board of Directors meeting held on Thursday, February 12, 2026. The primary approvals covered the declaration of financial results and a significant step in corporate structure simplification.
Financial Performance Highlights (Standalone)
The Board approved the unaudited standalone financial results for the quarter and nine months ending December 31, 2025. In the quarter ended December 31, 2025, the Company reported a Net Loss after tax of (Rs. 764 million), compared to a profit of Rs. 709 million in the corresponding quarter last year. Diluted Earnings Per Share (EPS) for the quarter stood at (Rs. 0.57).
For the nine months ended December 31, 2025, the Company recorded a net loss of (Rs. 138 million), with diluted EPS at (Rs. 0.11).
Acquisition of Remaining Biocon Biologics (BBL) Equity
The Board granted in-principle approval to acquire the remaining approximately ~2% paid-up equity share capital of Biocon Biologics Limited (BBL) on a fully diluted basis. These shares are held by employees of the Biocon Group and other shareholders. This move is the final step towards making BBL a wholly-owned subsidiary (WOS) of Biocon.
The consideration for acquiring these BBL shares will be discharged via a preferential allotment of Biocon’s equity shares. This proposal remains subject to necessary shareholder and regulatory approvals.
Post-Closing Context
This approval follows previous steps, including the increase of Biocon’s stake to approximately ~98% as informed on January 21, 2026. The Board Meeting commenced at 4:45 P.M. and concluded at 6:45 P.M.
Key Consolidated Financial Metrics (9 Months Ended Dec 31, 2025)
The consolidated results showed a Total Comprehensive Income/(Loss) attributable to shareholders of Rs. 11,903 million for the nine months ended December 31, 2025, compared to Rs. 6,688 million in the previous year period. Consolidated Diluted EPS for the nine months was Rs. 2.01.
Subsequent Events and Capital Changes
Subsequent to the reporting period, on January 14, 2026, the Company raised funds through a QIP for Rs. 41,500 million, partly to acquire BBL shares from Mylan Inc. and Edelweiss.
Furthermore, on January 05, 2026, the Company acquired 112,860,496 equity shares of BBL from various parties, partly via the preferential issuance of 79,312,534 Biocon equity shares, aggregating up to Rs. 32,183 million.
Exceptional Items Noted
The standalone results for the quarter ended December 31, 2025 included an exceptional loss of (Rs. 1,963 million), primarily related to inventory provision in BBL in connection with molecules assessed for liquidation.
Consolidated exceptional items for the quarter included a gain of Rs. 1,842 million related to the remeasurement of a derivative liability following the SSPA with Mylan Inc. concerning BBL share acquisition.
Source: BSE
